Mark Jeffrey DeLong, Chief Business & Strat Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 3,262 shares at $66.81 ($218K) on 2024-01-16, disclosed to the SEC on 2024-01-17.
Open-market sale of $218k APLS by Chief Business & Strat Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.81 | 1,631 | $109K | 50.0% |
| 2 | $66.81 | 1,631 | $109K | 50.0% |
| Total | $66.81 avg | 3,262 | $218K | 100% |
| Filing → |
| APLS | SELL | 2026-01-21 | $26K | — | Filing → |
| APLS | SELL | 2026-01-15 | $39K | — | Filing → |
| APLS | SELL | 2025-02-12 | $10K | — | Filing → |